Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

46.63 -1.83 (-3.78%)
Streaming Delayed Price Updated: 1:26 PM EST, Nov 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Novo Nordisk Has Downgraded Its Outlook for the Fourth Time This Year. Here's What Investors Need to Know.
Is the fourth time the charm for this Danish pharmaceutical giant? 
Via The Motley Fool
Topics Earnings
Trump Slashes Weight-Loss Drug Prices By Up To 74% In Deal With Lilly, Novo
The Trump administration announced deals Thursday with Eli Lilly and Novo Nordisk to slash the prices of their obesity drugs. 
Via Investor's Business Daily
Topics Government
Trump Announces Deals With Eli Lilly, Novo Nordisk To Lower Obesity Drug Prices
Via Stocktwits
Topics Government
Higher-Dose Of Wegovy Demonstrates Weight Loss And Cardiovascular Benefits
Novo Nordisk reports Wegovy users lost 21% body weight and saw improved heart health markers, as EMA and FDA reviews near for new doses. 
Via Benzinga
Pfizer To Raise Metsera Bid After Court Denies Attempt To Block Rival Deal
Delaware court denies Pfizer bid to block Metsera's Novo Nordisk deal as FTC flags antitrust risks and Pfizer prepares a higher counteroffer. 
Via Benzinga
Eli Lilly, Novo Nordisk Or A Dark Horse: Which Obesity-Drug Stock Are Retail Traders Most Bullish On Over Next 5 Years?
Via Stocktwits
Earnings Scheduled For November 5, 2025
 
Via Benzinga
Eli Lilly And Novo Nordisk Ignite Bullish Retail Frenzy Ahead Of TrumpRx Deals To Slash Prices For Weight-Loss Drugs
Via Stocktwits
Novo Nordisk Reportedly Refrains From Backing Down In Metsera Acquisition Battle, Sweetens Bid Further
According to an FT report, Pfizer now has two days to match Novo’s new bid or let its agreed-upon deal with Metsera fall through. 
Via Stocktwits
'It's Getting Ugly,' Analyst Says As Pfizer Escalates Its Gloves-Off Fight For Metsera
Metsera stock surged Thursday on reports Pfizer has matched Novo Nordisk's $10 billion bid to buy the obesity-focused biotech. 
Via Investor's Business Daily
Novo Nordisk A/S-Spons ADR (NYSE:NVO) Embodies Affordable Growth Strategy
Novo Nordisk (NVO) exemplifies affordable growth investing with strong expansion, reasonable valuation, high profitability, and a solid dividend. 
Via Chartmill
Trump Administration's Weight-Loss Drug Deal Is Sending This Novo Nordisk Rival Surging: Momentum Score Spikes
A leading pharmaceutical stock that goes head-to-head against Novo Nordisk A/S is surging amid a potential deal with the Trump administration. 
Via Benzinga
Topics Government
Novo Nordisk Snaps 11-Day Losing Streak After Court Rejects Pfizer’s Challenge To $10B Metsera Deal
Delaware Chancery Judge Morgan Zurn ruled that Pfizer’s objections did not justify delaying Novo’s $10 billion acquisition of obesity-drug startup Metsera. 
Via Stocktwits
Topics Law Enforcement
Obesity Drugmakers Face Shifting Tides: Novo Nordisk Plunges While Eli Lilly Soars
The burgeoning market for obesity and diabetes treatments, particularly GLP-1 receptor agonists, is witnessing a dramatic divergence in fortunes among its leading players. As of November 5, 2025, Novo... 
Via MarketMinute
Topics Economy
Novo Nordisk Q3 2025 Earnings Call Transcript
Novo Nordisk reported third-quarter financial results on Wednesday. The transcript from the company's earnings call has been provided below. 
Via Benzinga
Topics Earnings
Market Movers: Eli Lilly, Cadre, BP, Kellanova, and Teva Soar to 52-Week Highs Amidst Shifting Economic Tides
In a period marked by cautious optimism and strategic pivots, several prominent companies across diverse sectors have recently defied broader economic uncertainties to achieve significant 52-week... 
Via MarketMinute
Topics Economy Intellectual Property Supply Chain
Druckenmiller's Viking Trade Just Hit A Golden Cross — And A Sweet 36% Gain
Stanley Druckenmiller's firm bought Viking Therapeutics stock (VKTX) during Q2 at $25.33. Now up 36%, VKTX shows a Golden Cross. 
Via Benzinga
Prediction: Novo Nordisk Will Soar by 2026
Novo Nordisk stock just crashed -- but new drugs, smart acquisitions, and Wall Street upgrades could set up one of the biggest pharma rebounds of 2026. 
Via The Motley Fool
Novo Nordisk Skids After Cutting Its Outlook For The Third Time This Year
The Wegovy and Ozempic maker cut its 2025 sales outlook for the third time. 
Via Investor's Business Daily
Citigroup Says This Obesity Drugmaker's Stock Is Now a Buy
The bank's lead analyst recognizes the importance of getting in early with potentially game-changing drug development. 
Via The Motley Fool
Ozempic Maker Novo Nordisk Trims Growth Outlook For Obesity Drugs
Novo Nordisk Q3 profit drops on restructuring costs as GLP-1 and obesity drug sales rise; company narrows 2025 growth outlook. 
Via Benzinga
Here's Why Shares in Viking Therapeutics Shot Higher in October
Three factors took Viking's shares higher in the month. 
Via The Motley Fool
Can Novo Nordisk’s ‘Attractive’ Fundamentals Outweigh Slowing Wegovy Sales And A $149 Price Cap?
Novo Nordisk cut its 2025 profit and sales forecasts as slower GLP-1 growth and pricing pressure hit margins. 
Via Stocktwits
Topics Lawsuit
AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential
The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central... 
Via TokenRing AI
Topics Artificial Intelligence
Novo, Pfizer Are Battling To Buy The Future Of Weight-Loss — But Viking Already Owns It
Viking Global's $45 million investment in Metsera, a biotech company is caught in a bidding war between Pfizer and Novo Nordisk. 
Via Benzinga
Eli Lilly, Novo Nordisk Stocks Rise on Reported $149 Obesity Drug Deal with White House
Eli Lilly and Company (NYSE:LLY) shares are trading slightly lower on Tuesday after its previous gains following reports indicating the company is close to finalizing a White House agreement to provide... 
Via Benzinga
Pfizer, Novo Nordisk Intensify Fight For Metsera As Buyout Offers Continue To Climb
Novo Nordisk boosts its Metsera bid to $62.20 per share, valuing the company at $10 billion and outbidding Pfizer in the escalating takeover fight. 
Via Benzinga
Novo Sweetens Its Bid For Metsera, Pledging Up To $10 Billion
Novo Nordisk said it would pay up to $10 billion to acquire obesity-focused Metsera, topping Pfizer's recently hiked bid. 
Via Investor's Business Daily
Metsera Gets Revised Bids From Pfizer, Novo Nordisk: Here’s Why It Matters
Metsera said that it would be entitled to terminate its merger agreement with Pfizer if Novo’s proposal continues to be superior. 
Via Stocktwits
Should You Buy Novo Nordisk Stock Before the Huge Investor Update?
The company is preparing to launch a more convenient form of its weight loss treatment that has investors excited. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.